{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-006039","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.471409+00:00","generated_at":"2026-05-30T04:27:52.713897+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arbutus Q3 net loss $19.7M; imdusiran/AB-101 data upcoming; cash into Q4 2026","bullets":["Net loss $19.7M ($0.10 per share) vs $20.1M prior year; revenue fell to $1.3M from $4.7M on lower license and royalty income.","Cash and investments $130.8M; 2024 cash burn expected $63M-$67M; runway into Q4 2026.","Imdusiran HBsAg loss data from IM-PROVE I/II to be presented at AASLD Nov 2024; additional follow-up and nivolumab cohort data.","AB-101 oral PD-L1 inhibitor advanced to Part 3 in cHBV patients; preliminary data expected H1 2025.","LNP litigation vs Moderna trial set Sept 2025; Pfizer claim construction Dec 18, 2024; restructuring charge $3.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-006039","json":"https://secwatch.observer/filing/0001171843-24-006039.json","markdown":"https://secwatch.observer/filing/0001171843-24-006039.md","text":"https://secwatch.observer/filing/0001171843-24-006039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324006039/0001171843-24-006039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324006039/f8k_110624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:27:52.713897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}